Mga Batayang Estadistika
| LEI | HLYYNH7UQUORYSJQCN42 |
| CIK | 14272 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Bristol-Myers Squibb Company - Equity Right
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 31, 2025 |
Section 906 Certification Letter (furnished herewith). EXHIBIT 32b Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the "Report"), as filed with the |
|
| July 31, 2025 |
Exhibit 99.1 Bristol Myers Squibb Reports Second Quarter Financial Results for 2025 Performance Underscores Continued Execution Against Long-Term Growth Strategy •Second quarter revenues were $12.3 billion ◦Growth Portfolio revenues were $6.6 billion, +18% (+17% Ex-FX) •GAAP EPS was $0.64 and non-GAAP EPS was $1.46; Both figures include net impact of $(0.57) due to the Acquired IPRD charge associa |
|
| July 31, 2025 |
Section 906 Certification Letter (furnished herewith). EXHIBIT 32a Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, Christopher Boerner, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 (the "Report"), as filed with |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-01136 BRISTOL-MYERS SQUIBB C |
|
| July 31, 2025 |
Section 302 Certification Letter (filed herewith). EXHIBIT 31b CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David V. |
|
| July 31, 2025 |
Section 302 Certification Letter (filed herewith). EXHIBIT 31a CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christopher Boerner, certify that: 1. |
|
| July 31, 2025 |
q22025earningspresentati Not for Product Promotional Use Q2 2025 Results July 31, 2025 Not for Product Promotional UseQ2 2025 Results Forward Looking Statements and Non-GAAP Financial Information 2 This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. |
|
| July 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2025 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or organi |
|
| July 25, 2025 |
Exhibit 99.1 Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development Dr. Massacesi will join BMS August 1 and serve on the Executive Leadership Team Samit Hirawat, M.D., Executive Vice President, to step down from his role on August 1 and will depart BMS on November 1 PRINCETON, N.J., [BUSINESS WIRE] – Bristol Myers Squibb (NY |
|
| July 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2025 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or organi |
|
| June 6, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-01136 A. Full title of the plan and the address of plan, if d |
|
| June 6, 2025 |
EXHIBIT 23a – Consent of Independent Registered Public Accounting Firm Exhibit 23a Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statement Nos. |
|
| June 6, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-01136 A. Full title of the plan and the address of plan, if d |
|
| June 6, 2025 |
EXHIBIT 23a – Consent of Independent Registered Public Accounting Firm Exhibit 23a Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statement Nos. |
|
| June 6, 2025 |
EXHIBIT 23a – Consent of Independent Registered Public Accounting Firm Exhibit 23a Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statement Nos. |
|
| June 6, 2025 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-01136 A. Full title of the plan and the address of plan, if d |
|
| May 15, 2025 |
NOTIFICATION OF THE REMOVAL FROM LISTING AND REGISTRATION OF THE STATED SECURITIES The New York Stock Exchange hereby notifies the SEC of its intention to remove the entire class of the stated securities from listing and registration on the Exchange at the opening of business on May 27, 2025, pursuant to the provisions of Rule 12d2-2 (a). |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5) 2SEVENTY BIO, INC. (Name of Subject Company (Issuer)) DAYBREAK MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) (Names of Filing Persons (identify |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 BRISTOL-MYERS SQUIBB COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 1-1136 22-0790350 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4) 2SEVENTY BIO, INC. (Name of Subject Company (Issuer)) DAYBREAK MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) (Names of Filing Persons (identify |
|
| May 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) 2SEVENTY BIO, INC. (Name of Subject Company (Issuer)) DAYBREAK MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) (Names of Filing Persons (identify |
|
| April 24, 2025 |
Section 906 Certification Letter EXHIBIT 32b Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (the "Report"), as filed with th |
|
| April 24, 2025 |
Not for Product Promotional Use Q1 2025 Results April 24, 2025 Not for Product Promotional UseQ1 2025 Results Forward Looking Statements and Non-GAAP Financial Information 2 This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. |
|
| April 24, 2025 |
EXHIBIT 10b NOTICE OF GRANT OF MARKET SHARE UNITS UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN 2025 Market Share Units Award BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you an award of Market Share Units (such units, “MSUs”; such award, “Award”) under the 2021 Stock Award and Incentive Plan (the “Plan”), as described in this No |
|
| April 24, 2025 |
EXHIBIT 10c NOTICE OF GRANT OF RESTRICTED STOCK UNITS UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN 2025 Restricted Stock Units Award BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you an award of Restricted Stock Units (such units, “RSUs”; such award, “Award”) under the 2021 Stock Award and Incentive Plan (the “Plan”), as describe |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-01136 BRISTOL-MYERS SQUIBB |
|
| April 24, 2025 |
Section 302 Certification Letter EXHIBIT 31b CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David V. |
|
| April 24, 2025 |
EXHIBIT 10d NOTICE OF GRANT OF RESTRICTED STOCK UNITS UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN 2025 Restricted Stock Units Award BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you an award of Restricted Stock Units (such units, “RSUs”; such award, “Award”) under the 2021 Stock Award and Incentive Plan (the “Plan”), as describe |
|
| April 24, 2025 |
EXHIBIT 10f NOTICE OF GRANT OF RESTRICTED STOCK UNITS UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN 2025 Restricted Stock Units Award BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you an award of Restricted Stock Units (such units, “RSUs”; such award, “Award”) under the 2021 Stock Award and Incentive Plan (the “Plan”), as describe |
|
| April 24, 2025 |
EXHIBIT 10a NOTICE OF GRANT OF PERFORMANCE SHARE UNITS UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN 2025 Performance Share Units Award BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you an award of Performance Share Units (such units, “PSUs”; such award, “Award”) under the 2021 Stock Award and Incentive Plan (the “Plan”), as descr |
|
| April 24, 2025 |
Exhibit 99.1 Bristol Myers Squibb Reports First Quarter Financial Results for 2025 Results Reflect Continued Growth Portfolio Momentum and Disciplined Execution •First quarter revenues were $11.2 billion, -6% (-4% Ex-FX) ◦Growth Portfolio revenues were $5.6 billion, +16% (+18% Ex-FX) •GAAP EPS was $1.20 and non-GAAP EPS was $1.80 •Raising 2025 revenue guidance to a range of ~$45.8 billion to $46.8 |
|
| April 24, 2025 |
Section 302 Certification Letter EXHIBIT 31a CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christopher Boerner, certify that: 1. |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2025 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or organ |
|
| April 24, 2025 |
EXHIBIT 10e NOTICE OF GRANT OF RESTRICTED STOCK UNITS UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN 2025 Restricted Stock Units Award BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you an award of Restricted Stock Units (such units, “RSUs”; such award, “Award”) under the 2021 Stock Award and Incentive Plan (the “Plan”), as describe |
|
| April 24, 2025 |
Bristol-Myers Squibb Company Severance Benefits Plan (filed herewith). EXHIBIT 10g BRISTOL-MYERS SQUIBB COMPANY SEVERANCE BENEFITS PLAN AND SUMMARY PLAN DESCRIPTION 1. |
|
| April 24, 2025 |
Section 906 Certification Letter EXHIBIT 32a Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, Christopher Boerner, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (the "Report"), as filed wit |
|
| April 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) 2SEVENTY BIO, INC. (Name of Subject Company (Issuer)) DAYBREAK MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) (Names of Filing Persons (identify |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) 2SEVENTY BIO, INC. (Name of Subject Company (Issuer)) DAYBREAK MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) (Names of Filing Persons (identify |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| April 14, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) 2SEVENTY BIO, INC. |
|
| April 14, 2025 |
Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of 2SEVENTY BIO, INC. |
|
| April 14, 2025 |
Exhibit (a)(1)(ii) Letter of Transmittal to Tender Shares of Common Stock of 2SEVENTY BIO, INC. |
|
| April 14, 2025 |
Exhibit (a)(1)(iii) Offer to Purchase for Cash All Outstanding Shares of Common Stock of 2SEVENTY BIO, INC. |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 2SEVENTY BIO, INC. (Name of Subject Company (Issuer)) DAYBREAK MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) (Names of Filing Persons (identifying status as offe |
|
| April 14, 2025 |
Exhibit (d)(2) TENDER AND SUPPORT AGREEMENT This Tender and Support Agreement (this “Agreement”), dated as of March 10, 2025, is entered into by and between Bristol-Myers Squibb Company, a Delaware corporation (“Parent”), and the undersigned stockholder of 2seventy bio, Inc. |
|
| April 14, 2025 |
Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| April 14, 2025 |
TABLE OF CONTENTS Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of 2SEVENTY BIO, INC. |
|
| April 14, 2025 |
Exhibit (a)(1)(v) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of 2SEVENTY BIO, INC. |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defini |
|
| March 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 2SEVENTY BIO, INC. (Name of Subject Company (Issuer)) DAYBREAK MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Offeror) (Name of Filing Persons (identifying status as offeror, issuer |
|
| March 13, 2025 |
Exhibit 99.1 -BMS CONFIDENTIAL- From: Lynelle Hoch To: 2seventy bio employees Date: Thursday, 3/13 Subject: Continuing our work together to bring Abecma to patients Dear 2seventy bio colleagues, Monday was an important day with the announcement that Bristol Myers Squibb (BMS) has entered into an agreement to acquire 2seventy bio. As the president of BMS’ Cell Therapy Organization, I have had a fro |
|
| February 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 (February 14, 2025) BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of |
|
| February 12, 2025 |
Section 906 Certification Letter (filed herewith). EXHIBIT 32a Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U. S. C. Section 1350, I, Christopher Boerner, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (the Report), as filed with t |
|
| February 12, 2025 |
Section 302 Certification Letter (filed herewith). EXHIBIT 31b CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David V. |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-01136 BRISTOL-MYERS SQUIBB COMPA |
|
| February 12, 2025 |
Subsidiaries of the Registrant (filed herewith). EXHIBIT 21 Subsidiaries of Bristol-Myers Squibb Company The following are subsidiaries of the Bristol-Myers Squibb Company at December 31, 2024. |
|
| February 12, 2025 |
Section 906 Certification Letter (filed herewith). EXHIBIT 32b Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U. S. C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (the Report), as filed with the S |
|
| February 12, 2025 |
Section 302 Certification Letter (filed herewith). EXHIBIT 31a CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christopher Boerner, certify that: 1. |
|
| February 6, 2025 |
Exhibit 99.1 Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2024 Performance Reflects Progress Toward Delivering Sustained, Top-Tier Growth •Fourth Quarter Revenues were $12.3 Billion, Increasing 8% (+9% Adjusting for Foreign Exchange); GAAP Earnings Per Share (EPS) was $0.04 and Non-GAAP EPS was $1.67 ◦Growth Portfolio Revenues were $6.4 Billion, Increasing 21% (+ |
|
| February 6, 2025 |
Not for Product Promotional Use Q4 2024 Results February 6, 2025 Not for Product Promotional UseQ4 2024 Results Forward Looking Statements and Non-GAAP Financial Information 2 This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2025 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or org |
|
| January 13, 2025 |
Exhibit 99.1 43rd Annual J.P. Morgan Healthcare Conference January 13th, 2025 Christopher Boerner, Ph.D., Board Chair and Chief Executive Officer Forward Looking Statements and Non-GAAP Financial Information 2 This presentation (as well as the oral statements made with respect to the information contained in this presentation) contains statements about Bristol-Myers Squibb Company’s (the “Company” |
|
| January 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or org |
|
| December 13, 2024 |
Exhibit 25.1 = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM T-1 STATEMENT OF ELIGIBILITY UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION 305(b)(2) || THE BANK OF NE |
|
| December 13, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Bristol-Myers Squibb Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registratio |
|
| December 13, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 23a CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Registration Statement on Form S-3 of our reports dated February 12, 2024 relating to the financial statements of Bristol-Myers Squibb Company, and the effectiveness of Bristol-Myers Squibb Company’s internal control over financial reporting, appearing in the Annual Report on Form 10-K of Bristol-Myers Squibb Company for the year ended December 31, 2023. |
|
| December 13, 2024 |
As filed with the Securities and Exchange Commission on December 13, 2024 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on December 13, 2024 No. |
|
| November 13, 2024 |
RNA / Avidity Biosciences, Inc. / BRISTOL MYERS SQUIBB CO - SC 13G/A Passive Investment SC 13G/A 1 ef20038544sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Avidity Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05370A108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statemen |
|
| November 13, 2024 |
QURE / uniQure N.V. / BRISTOL MYERS SQUIBB CO - SC 13G/A Passive Investment SC 13G/A 1 ef20038542sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* uniQure N.V. (Name of Issuer) Ordinary Shares (Title of Class of Securities) N90064101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| November 13, 2024 |
IKNA / Ikena Oncology, Inc. / BRISTOL MYERS SQUIBB CO - SC 13G/A Passive Investment SC 13G/A 1 ef20038543sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ikena Oncology, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45175G108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the app |
|
| November 13, 2024 |
QTTB / Q32 Bio Inc. / BRISTOL MYERS SQUIBB CO - SC 13G Passive Investment SC 13G 1 ef20038540sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Q32 Bio Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 746964105 (CUSIP Number) March 25, 2024 (Date of Event Which Requires Filing of this Statement) Check the Appropriat |
|
| October 31, 2024 |
Section 302 Certification Letter. EXHIBIT 31b CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David V. |
|
| October 31, 2024 |
q32024earningspresentati Not for Product Promotional Use Q3 2024 Results October 31, 2024 Not for Product Promotional UseQ3 2024 Results Forward Looking Statements and Non-GAAP Financial Information 2 This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. |
|
| October 31, 2024 |
Section 906 Certification Letter. EXHIBIT 32b Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Report"), as filed wit |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-01136 BRISTOL-MYERS SQU |
|
| October 31, 2024 |
Section 906 Certification Letter. EXHIBIT 32a Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, Christopher Boerner, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Report"), as filed |
|
| October 31, 2024 |
Exhibit 99.1 Bristol Myers Squibb Reports Third Quarter Financial Results for 2024 Performance Reflects Continued Focus on Near-Term Execution and Building a Foundation for Long-Term Sustainable Growth •Third Quarter Revenues were $11.9 Billion, increasing 8% (+10% Adjusting for Foreign Exchange) •Growth Portfolio Revenues were $5.8 Billion, increasing 18% (+20% Adjusting for Foreign Exchange) •GA |
|
| October 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 31, 2024 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or org |
|
| October 31, 2024 |
Section 302 Certification Letter. EXHIBIT 31a CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christopher Boerner, certify that: 1. |
|
| October 4, 2024 |
PRME / Prime Medicine, Inc. / BRISTOL MYERS SQUIBB CO - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Prime Medicine, Inc. (Name of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securities) 74168J101 (CUSIP Number) September 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| July 26, 2024 |
Section 906 Certification Letter. EXHIBIT 32a Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, Christopher Boerner, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the "Report"), as filed with |
|
| July 26, 2024 |
Section 302 Certification Letter. EXHIBIT 31a CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christopher Boerner, certify that: 1. |
|
| July 26, 2024 |
q22024earningspresentati Q2 2024 Results July 26, 2024 Q2 2024 Results Not for Product Promotional Use Forward Looking Statements and Non-GAAP Financial Information 2 This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. |
|
| July 26, 2024 |
Amended and Restated Certificate of Incorporation of Bristol-Myers Squibb Company, as Exhibit 3a AMENDED AND RESTATED CERTIFICATE OF INCORPORATION of BRISTOL-MYERS SQUIBB COMPANY This Amended and Restated Certificate of Incorporation of Bristol-Myers Squibb Company, originally incorporated as Bristol-Myers Company, was duly proposed by the board of directors of the corporation and adopted by the stockholders in accordance with the provisions of Sections 242 and 245 of the General Corporation Law of the State of Delaware. |
|
| July 26, 2024 |
Section 906 Certification Letter. EXHIBIT 32b Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the "Report"), as filed with the |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2024 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or organi |
|
| July 26, 2024 |
Section 302 Certification Letter. EXHIBIT 31b CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David V. |
|
| July 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-01136 BRISTOL-MYERS SQUIBB C |
|
| July 26, 2024 |
Exhibit 99.1 Bristol Myers Squibb Reports Second Quarter Financial Results for 2024 Results Underscore Continued Progress on Commercial Execution, Driving the Growth Portfolio and Pipeline Advancement •Second Quarter Revenues were $12.2 Billion, increasing 9% (+11% Adjusting for Foreign Exchange) •Growth Portfolio Revenues were $5.6 Billion, increasing 18% (+21% Adjusting for Foreign Exchange) •GA |
|
| June 25, 2024 |
EXHIBIT 23a – Consent of Independent Registered Public Accounting Firm Exhibit 23a Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statement Nos. |
|
| June 25, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-01136 A. Full title of the plan and the address of plan, if d |
|
| June 25, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-01136 A. Full title of the plan and the address of plan, if d |
|
| June 25, 2024 |
EXHIBIT 23a – Consent of Independent Registered Public Accounting Firm Exhibit 23a Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statement Nos. |
|
| June 25, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-01136 A. Full title of the plan and the address of plan, if d |
|
| June 25, 2024 |
EXHIBIT 23a – Consent of Independent Registered Public Accounting Firm Exhibit 23a Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statement Nos. |
|
| June 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2024 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or organi |
|
| June 18, 2024 |
Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors Exhibit 99.1 Bristol Myers Squibb Elects Michael R. McMullen to Board of Directors (Princeton, N.J., June 18, 2024) – Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected independent director Michael R. McMullen to the Board, effective July 1, 2024. Mr. McMullen will serve as a member of the Audit Committee of the Board of Directors. “We are pleased to welcome M |
|
| May 9, 2024 |
Exhibit 3a CERTIFICATE OF AMENDMENT TO THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF BRISTOL-MYERS SQUIBB COMPANY Pursuant to Section 242 of the General Corporation Law of the State of Delaware Bristol-Myers Squibb Company, a corporation duly organized and existing under the General Corporation Law of the State of Delaware (the “Corporation”), does hereby certify that: 1. |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 BRISTOL-MYERS SQUIBB COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 1-1136 22-0790350 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 25, 2024 |
Section 906 Certification Letter. EXHIBIT 32b Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the "Report"), as filed with th |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2024 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or organ |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-01136 BRISTOL-MYERS SQUIBB |
|
| April 25, 2024 |
q12024earningspresentati Q1 2024 Results April 25, 2024 Q1 2024 Results Not for Product Promotional Use Forward Looking Statements and Non-GAAP Financial Information 2 This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. |
|
| April 25, 2024 |
Section 906 Certification Letter. EXHIBIT 32a Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, Christopher Boerner, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the "Report"), as filed wit |
|
| April 25, 2024 |
Section 302 Certification Letter. EXHIBIT 31b CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David V. |
|
| April 25, 2024 |
Section 302 Certification Letter. EXHIBIT 31a CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christopher Boerner, certify that: 1. |
|
| April 25, 2024 |
Exhibit 99.1 Bristol Myers Squibb Reports First Quarter Financial Results for 2024 Performance Reflects Execution and Actions to Strengthen the Company's Long-Term Growth Profile •First Quarter Revenues were $11.9 Billion, increasing 5% (+6% Adjusting for Foreign Exchange) ◦Growth Portfolio Revenues were $4.8 Billion, increasing 8% (+11% Adjusting for Foreign Exchange) •Strengthened Long-Term Grow |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ |
|
| March 28, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 18, 2024 |
Exhibit 99.1 Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio KarXT, Karuna’s Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Multi-Billion Dollar Sales Potential Across Multiple Indications PRINCETON, N.J. – March 18, 2024 – Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acqu |
|
| March 18, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2024 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or organ |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2024 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 23, 2024 |
Exhibit (a)(5)(xii) Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer PRINCETON, N. |
|
| February 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) RAYZEBIO, INC. (Name of Subject Company (Issuer)) RUDOLPH MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) (Names of Filing Persons (identifying s |
|
| February 22, 2024 |
Exhibit 1.1 Execution Version UNDERWRITING AGREEMENT, dated as of February 14, 2024 Bristol-Myers Squibb Company $500,000,000 Floating Rate Notes due 2026 $1,000,000,000 4.950% Notes due 2026 $1,000,000,000 4.900% Notes due 2027 $1,750,000,000 4.900% Notes due 2029 $1,250,000,000 5.100% Notes due 2031 $2,500,000,000 5.200% Notes due 2034 $500,000,000 5.500% Notes due 2044 $2,750,000,000 5.550% Not |
|
| February 22, 2024 |
Exhibit 4.1 Execution Version BRISTOL-MYERS SQUIBB COMPANY and THE BANK OF NEW YORK MELLON, as Trustee FIFTEENTH SUPPLEMENTAL INDENTURE Dated as of February 22, 2024 to INDENTURE Dated as of June 1, 1993 $500,000,000 Floating Rate Notes due 2026 $1,000,000,000 4.950% Notes due 2026 $1,000,000,000 4.900% Notes due 2027 $1,750,000,000 4.900% Notes due 2029 $1,250,000,000 5.100% Notes due 2031 $2,500 |
|
| February 22, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 (February 14, 2024) BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of |
|
| February 16, 2024 |
February 16, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Laura McKenzie and Christina Chalk, Division of Corporation Finance, Office of Mergers & Acquisitions Re: Bristol-Myers Squibb Company RayzeBio, Inc. Schedule TO-T filed January 25, 2024 File No. 005-94159 Dear Ms. McKenzie and Ms. Chalk: This letter |
|
| February 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) RAYZEBIO, INC. (Name of Subject Company (Issuer)) RUDOLPH MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) (Names of Filing Persons (identifying |
|
| February 16, 2024 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-261623 PROSPECTUS SUPPLEMENT (to Prospectus dated December 13, 2021) $13,000,000,000 $500,000,000 Floating Rate Notes due 2026 $1,000,000,000 4.950% Notes due 2026 $1,000,000,000 4.900% Notes due 2027 $1,750,000,000 4.900% Notes due 2029 $1,250,000,000 5.100% Notes due 2031 $2,500,000,000 5.200% Notes due 2034 $500,000,000 5 |
|
| February 16, 2024 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Bristol-Myers Squibb Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule(1) Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Debt Floating Rate Notes due 2026 Rule 457(r) $500,000,000 100. |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or or |
|
| February 15, 2024 |
Issuer Free Writing Prospectus, dated February 14, 2024 Filed Pursuant to Rule 433 of the Securities Act of 1933 Registration Statement No. |
|
| February 14, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2024 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or or |
|
| February 14, 2024 |
Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC Exhibit 99.1 Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLC (Princeton, N.J., February 14, 2024) – Bristol Myers Squibb (NYSE: BMY) today announced that it recently became aware of an unsolicited “mini-tender” offer by Tutanota LLC (“Tutanota”) to purchase up to five hundred thousand shares of Bristol Myers Squibb’s common stock, representing significantly |
|
| February 13, 2024 |
Section 302 Certification Letter (filed herewith). EXHIBIT 31b CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David V. |
|
| February 13, 2024 |
EXHIBIT 10bb RESTRICTED STOCK UNITS AGREEMENT UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you an award of Restricted Stock Units (“RSUs” or “Award”) under the 2021 Stock Award and Incentive Plan (the “Plan”), on the terms and conditions specified in this Restricted Stock Units Agreement (including Addendum A and Addendum B, the “Agreement”), the Plan, and the Prospectus (which summarizes various aspects of the Plan, including your risk in participating in the Plan, restrictions on resales of delivered shares, federal income tax consequences, and other Plan information). |
|
| February 13, 2024 |
EXHIBIT 10dd RESTRICTED STOCK UNITS AGREEMENT UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you an award of Restricted Stock Units (“RSUs” or “Award”) under the 2021 Stock Award and Incentive Plan (the “Plan”), on the terms and conditions specified in this Restricted Stock Units Agreement (including Addendum A and Addendum B, the “Agreement”), the Plan, and the Prospectus (which summarizes various aspects of the Plan, including your risk in participating in the Plan, restrictions on resales of delivered shares, federal income tax consequences, and other Plan information). |
|
| February 13, 2024 |
EXHIBIT 10ee RESTRICTED STOCK UNITS AGREEMENT UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you an award of Restricted Stock Units (“RSUs” or “Award”) under the 2021 Stock Award and Incentive Plan (the “Plan”), on the terms and conditions specified in this Restricted Stock Units Agreement (including Addendum A and Addendum B, the “Agreement”), the Plan and the Prospectus (which summarizes various aspects of the Plan, including your risk in participating in the Plan, restrictions on resales of delivered shares, federal income tax consequences, and other Plan information). |
|
| February 13, 2024 |
EXHIBIT 10i PERFORMANCE SHARE UNITS AGREEMENT UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN 2024-2026 Performance Share Units Award BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you an award of Performance Share Units (“PSUs” or “Award”) under the 2021 Stock Award and Incentive Plan (the “Plan”), on the terms and conditions specified in this Performance Share Units Agreement (including, Exhibit A, Addendum A and Addendum B, the “Agreement”), the Plan, and the Prospectus (which summarizes various aspects of the Plan, including your risk in participating in the Plan, restrictions on resales of delivered shares, federal income tax consequences, and other Plan information). |
|
| February 13, 2024 |
Policies and Procedures for the Recoupment of EXHIBIT 97 Policies and Procedures for the Recoupment of Compensation for Accounting Restatement Introduction/Purpose Bristol-Myers Squibb Company (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and that reinforces the Company’s pay-for-performance compensation philosophy. |
|
| February 13, 2024 |
Subsidiaries of the Registrant (filed herewith). EXHIBIT 21 Subsidiaries of Bristol-Myers Squibb Company The following are subsidiaries of the Bristol-Myers Squibb Company at December 31, 2023. |
|
| February 13, 2024 |
EXHIBIT 10ff RESTRICTED STOCK UNITS AGREEMENT UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you an award of Restricted Stock Units (“RSUs” or “Award”) under the 2021 Stock Award and Incentive Plan (the “Plan”), on the terms and conditions specified in this Restricted Stock Units Agreement (including Addendum A and Addendum B, the “Agreement”), the Plan and the Prospectus (which summarizes various aspects of the Plan, including your risk in participating in the Plan, restrictions on resales of delivered shares, federal income tax consequences, and other Plan information). |
|
| February 13, 2024 |
Section 906 Certification Letter (filed herewith). EXHIBIT 32a Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U. S. C. Section 1350, I, Christopher Boerner, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the Report), as filed with t |
|
| February 13, 2024 |
Subject to Completion, dated February 13, 2024 TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(2) Registration No. 333-261623 Subject to Completion, dated February 13, 2024 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus do not constitute an offer to sell or the solicitation of an offer to buy, no |
|
| February 13, 2024 |
Section 302 Certification Letter (filed herewith). EXHIBIT 31a CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Christopher Boerner, certify that: 1. |
|
| February 13, 2024 |
BMY / Bristol-Myers Squibb Company / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0481-bristolmyerssquibbco.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Bristol-Myers Squibb Co Title of Class of Securities: Common Stock CUSIP Number: 110122108 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to |
|
| February 13, 2024 |
Standard Operating Procedure BMS-SOP-5k: Securities Trading ( EXHIBIT 19 Standard Operating Procedure BMS-SOP-5k: Securities Trading PURPOSE To provide the Bristol-Myers Squibb Company (BMS) principles and expectations to prevent the illegal trading of Securities based on Material Non-Public Information (or “Insider Trading”) and other restrictions on trading of Securities. |
|
| February 13, 2024 |
Section 906 Certification Letter (filed herewith). EXHIBIT 32b Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U. S. C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Annual Report on Form 10-K for the year ended December 31, 2023 (the Report), as filed with the S |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-01136 BRISTOL-MYERS SQUIBB COMPA |
|
| February 13, 2024 |
Form of Market Share Units Agreement under the 2021 Stock Award and Incentive Plan ( EXHIBIT 10gg MARKET SHARE UNITS AGREEMENT UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you an award of Market Share Units (“MSUs” or “Award”) under the 2021 Stock Award and Incentive Plan (the “Plan”), on the terms and conditions specified in this Market Share Units Agreement (including, Exhibit A, Addendum A and Addendum B, the “Agreement”), the Plan, and the Prospectus (which summarizes various aspects of the Plan, including your risk in participating in the Plan, restrictions on resales of delivered shares, federal income tax consequences, and other Plan information). |
|
| February 13, 2024 |
EXHIBIT 10cc RESTRICTED STOCK UNITS AGREEMENT UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you an award of Restricted Stock Units (“RSUs” or “Award”) under the 2021 Stock Award and Incentive Plan (the “Plan”), on the terms and conditions specified in this Restricted Stock Units Agreement (including Addendum A and Addendum B, the “Agreement”), the Plan, and the Prospectus (which summarizes various aspects of the Plan, including your risk in participating in the Plan, restrictions on resales of delivered shares, federal income tax consequences, and other Plan information). |
|
| February 12, 2024 |
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period Exhibit (a)(5)(xi) Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period PRINCETON, NJ & SAN DIEGO, CA – February 12, 2024 – Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. |
|
| February 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) RAYZEBIO, INC. (Name of Subject Company (Issuer)) RUDOLPH MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) (Names of Filing Persons (identifying |
|
| February 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2024 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or org |
|
| February 2, 2024 |
q42023earningspresentati Q4 2023 Results February 2, 2024 Q4 2023 Results Not for Product Promotional Use Forward Looking Statements and Non-GAAP Financial Information 2 This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. |
|
| February 2, 2024 |
Exhibit 99.1 Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023 Results Reflect Continued Strength of In-Line and New Products, Pipeline Execution and Business Development Activity, Supporting Growth Momentum into 2024 •Reports Fourth Quarter Revenues of $11.5 Billion; GAAP EPS of $0.87 and Non-GAAP EPS of $1.70 ◦In-Line and New Product Portfolio Revenues Increase |
|
| January 25, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) RAYZEBIO, INC. |
|
| January 25, 2024 |
Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of RAYZEBIO, INC. |
|
| January 25, 2024 |
Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of RAYZEBIO, INC. |
|
| January 25, 2024 |
Exhibit (d)(3) CONFIDENTIALITY AGREEMENT THIS CONFIDENTIALITY AGREEMENT (“Agreement”) is being entered into as of December 16, 2023, between RayzeBio, Inc. |
|
| January 25, 2024 |
Exhibit (a)(1)(iii) Offer to Purchase for Cash All Outstanding Shares of Common Stock of RAYZEBIO, INC. |
|
| January 25, 2024 |
[Remainder of page intentionally left blank; signature page follows] Exhibit (d)(2) JOINDER This Joinder to the Agreement and Plan of Merger (this “Joinder”), is made and entered into as of December 26, 2023, by Rudolph Merger Sub Inc. |
|
| January 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 RAYZEBIO, INC. (Name of Subject Company (Issuer)) RUDOLPH MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Parent of Offeror) (Names of Filing Persons (identifying status as offeror |
|
| January 25, 2024 |
TABLE OF CONTENTS Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of RAYZEBIO, INC. |
|
| January 25, 2024 |
Exhibit (a)(1)(v) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| January 8, 2024 |
Exhibit 99.1 January 8, 2024 J.P. Morgan Presentation Forward looking statements and non-GAAP financial information 2 This presentation (as well as the oral statements made with respect to information contained in this presentation) contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, r |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 BRISTOL-MYERS SQUIBB COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 1-1136 22-0790350 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 26, 2023 |
Transaction Infographic dated December 26, 2023 Exhibit 99.2 Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform » Lead program, RYZ101, in Phase 3 development for treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and early-stage development for treatment of small cell lung cancer and potentially ot |
|
| December 26, 2023 |
Letter to RayzeBio Employees dated December 26, 2023 Exhibit 99.5 BMS-RYZB Letter to RYZB Employees Subject: Welcome to the Bristol Myers Squibb Team! To: RayzeBio Employees Date: December 26, 2023 Dear RayzeBio Team, On behalf of everyone at Bristol Myers Squibb, I am writing to share how excited we are about the proposed transaction. We deeply admire what RayzeBio has accomplished, and all of us at BMS are impressed by your technology, differentia |
|
| December 26, 2023 |
Enterprise Letter dated December 26, 2023 Exhibit 99.4 BMS-RYZB BMS Employee Letter Subject: Broadening our Oncology Capabilities with Acquisition of RayzeBio To: Bristol Myers Squibb Employees Date: December 26, 2023 Dear Colleagues, We hope that you are reading this following a quiet and restful Shutdown Week. We are excited to share that today, December 26, 2023, we announced an agreement to acquire RayzeBio, a radiopharmaceutical ther |
|
| December 26, 2023 |
Joint Press Release dated December 26, 2023 Exhibit 99.1 Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs, to Bristol Myers Squibb’s Leading Oncology Franchise Lead Program, RYZ101, in Phase 3 Development for Treatment of Gastroenteropancreatic Neur |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 RAYZEBIO, INC. (Name of Subject Company (Issuer)) RUDOLPH MERGER SUB INC. (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Offeror) (Name of Filing Persons (identifying status as offeror, issuer or o |
|
| December 26, 2023 |
Bristol Myers Squibb Social Media Content dated December 26, 2023 Exhibit 99.3 Social Media Content Twitter/X LinkedIn Additional Information about the Tender Offer and Where to Find It The tender offer described in this communication has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of RayzeBio or any other securities, nor is it a |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule14a-6( |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or Other Jurisdiction of Incorporation) (Com |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or Other Jurisdiction of Incorporation) (Com |
|
| December 22, 2023 |
Exhibit 99.1 Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Treatment for Alzheimer’s Disease Psychosis, with Prom |
|
| December 22, 2023 |
Exhibit 99.1 Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in-Disease Treatment for Alzheimer’s Disease Psychosis, with Prom |
|
| December 4, 2023 |
RNA / Avidity Biosciences Inc / BRISTOL MYERS SQUIBB CO - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Avidity Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 05370A108 (CUSIP Number) November 27, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate th |
|
| November 13, 2023 |
Exhibit 4.1 Bristol-Myers Squibb Company and THE BANK OF NEW YORK MELLON, as Trustee FOURTEENTH SUPPLEMENTAL INDENTURE Dated as of November 13, 2023 to INDENTURE Dated as of June 1, 1993 $1,000,000,000 5.750% Notes due 2031 $1,000,000,000 5.900% Notes due 2033 $1,250,000,000 6.250% Notes due 2053 $1,250,000,000 6.400% Notes due 2063 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 2 Section 1.01 Defin |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 (October 30, 2023) BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of |
|
| November 13, 2023 |
Exhibit 1.1 Execution Version UNDERWRITING AGREEMENT, dated as of October 30, 2023 Bristol-Myers Squibb Company $1,000,000,000 5.750% Notes due 2031 $1,000,000,000 5.900% Notes due 2033 $1,250,000,000 6.250% Notes due 2053 $1,250,000,000 6.400% Notes due 2063 New York, New York October 30, 2023 To the Representatives named in Schedule I hereto of the Underwriters named in Schedule II hereto Ladies |
|
| November 1, 2023 |
Calculation of Filing Fee Tables Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Bristol-Myers Squibb Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule(1) Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Debt 5. |
|
| November 1, 2023 |
TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-261623 PROSPECTUS SUPPLEMENT (to Prospectus dated December 13, 2021) $4,500,000,000 $1,000,000,000 5.750% Notes due 2031 $1,000,000,000 5.900% Notes due 2033 $1,250,000,000 6.250% Notes due 2053 $1,250,000,000 6.400% Notes due 2063 We are offering $1,000,000,000 aggregate principal amount of 5.750% Notes due 2031 ( |
|
| October 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2023 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of in |
|
| October 30, 2023 |
Issuer Free Writing Prospectus, dated October 30, 2023 Filed Pursuant to Rule 433 of the Securities Act of 1933 Registration Statement No. |
|
| October 30, 2023 |
Subject to Completion, dated October 30, 2023 TABLE OF CONTENTS The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| October 26, 2023 |
Section 302 Certification Letter. EXHIBIT 31a CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Giovanni Caforio, certify that: 1. |
|
| October 26, 2023 |
Section 906 Certification Letter. EXHIBIT 32a Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, Giovanni Caforio, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the "Report"), as filed wi |
|
| October 26, 2023 |
Q3 2023 Results October 26, 2023 Exhibit 99.2 Q3 2023 Results Not for Product Promotional Use Forward Looking Statements and Non-GAAP Financial Information 2 This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-l |
|
| October 26, 2023 |
Section 906 Certification Letter. EXHIBIT 32b Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the "Report"), as filed wit |
|
| October 26, 2023 |
Section 302 Certification Letter. EXHIBIT 31b CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David V. |
|
| October 26, 2023 |
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023 Exhibit 99.1 Bristol Myers Squibb Reports Third Quarter Financial Results for 2023 •Reports Third Quarter Revenues of $11.0 Billion •Posts Third Quarter GAAP Earnings Per Share of $0.93 and Non-GAAP EPS of $2.00; Includes Net Impact of ($0.03) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income •Reports Third Quarter Revenue Growth for In-Line Products and New Pro |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-01136 BRISTOL-MYERS SQU |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or org |
|
| October 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule14a-6( |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or organ |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2023 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or organi |
|
| July 27, 2023 |
Section 906 Certification Letter. EXHIBIT 32b Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (the "Report"), as filed with the |
|
| July 27, 2023 |
Section 906 Certification Letter. EXHIBIT 32a Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, Giovanni Caforio, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023 (the "Report"), as filed with th |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-01136 BRISTOL-MYERS SQUIBB C |
|
| July 27, 2023 |
Section 302 Certification Letter. EXHIBIT 31b CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David V. |
|
| July 27, 2023 |
Section 302 Certification Letter. EXHIBIT 31a CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Giovanni Caforio, certify that: 1. |
|
| July 27, 2023 |
q22023earningspresentati Q2 2023 Results July 27, 2023 Q2 2023 Results Not for Product Promotional Use Forward Looking Statements and Non-GAAP Financial Information 2 This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. |
|
| July 27, 2023 |
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023 Exhibit 99.1 Bristol Myers Squibb Reports Second Quarter Financial Results for 2023 •Reports Second Quarter Revenues of $11.2 Billion •Posts Second Quarter GAAP Earnings Per Share of $0.99 and Non-GAAP EPS of $1.75; Includes Net Impact of ($0.05) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income •Reports Second Quarter Revenue Growth for In-Line Products and New |
|
| June 8, 2023 |
EXHIBIT 23a – Consent of Independent Registered Public Accounting Firm Exhibit 23a Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statement Nos. |
|
| June 8, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-01136 A. Full title of the plan and the address of plan, if d |
|
| June 8, 2023 |
EXHIBIT 23a – Consent of Independent Registered Public Accounting Firm Exhibit 23a Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statement Nos. |
|
| June 8, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-01136 A. Full title of the plan and the address of plan, if d |
|
| June 8, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K x ANNUAL REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ¨ TRANSITION REPORT PURSUANT TO SECTION 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-01136 A. Full title of the plan and the address of plan, if d |
|
| June 8, 2023 |
EXHIBIT 23a – Consent of Independent Registered Public Accounting Firm Exhibit 23a Consent of Independent Registered Public Accounting Firm We consent to the incorporation by reference in Registration Statement Nos. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2023 BRISTOL-MYERS SQUIBB COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 1-1136 22-0790350 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 27, 2023 |
q12023earningspresentati Q1 2023 Results April 27, 2023 Q1 2023 Results Not for Product Promotional Use Forward Looking Statements and Non-GAAP Financial Information 2 This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. |
|
| April 27, 2023 |
Section 906 Certification Letter. EXHIBIT 32a Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, Giovanni Caforio, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the "Report"), as filed with t |
|
| April 27, 2023 |
Section 906 Certification Letter. EXHIBIT 32b Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 (the "Report"), as filed with th |
|
| April 27, 2023 |
Bristol Myers Squibb Reports First Quarter Financial Results for 2023 Exhibit 99.1 Bristol Myers Squibb Reports First Quarter Financial Results for 2023 •Reports First Quarter Revenues of $11.3 Billion •Posts First Quarter GAAP Earnings Per Share of $1.07 and Non-GAAP EPS of $2.05; Includes Net Impact of ($0.01) Per Share for GAAP and Non-GAAP EPS Due to Acquired IPRD Charges and Licensing Income •Delivers Strong Revenue Growth of 8% from In-Line Products and New Pr |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-01136 BRISTOL-MYERS SQUIBB |
|
| April 27, 2023 |
Section 302 Certification Letter. EXHIBIT 31b CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David V. |
|
| April 27, 2023 |
Section 302 Certification Letter. EXHIBIT 31a CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Giovanni Caforio, certify that: 1. |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2023 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or organ |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2023 BRISTOL-MYERS SQUIBB COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 001-01136 22-0790350 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 26, 2023 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Bristol Myers Squibb Announces Leadership Transition Plan Giovanni Caforio, MD, Bristol Myers Squibb Chairman and CEO, to Retire as CEO, Effective November 1, 2023; Will Continue as Executive Chairman of the Board Christopher Boerner, PhD, EVP, Chief Commercialization Officer, Appointed EVP, Chief Operating Officer, Effective Immediately; to Succeed Giovanni Cafo |
|
| April 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 21, 2023 BRISTOL-MYERS SQUIBB COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 001-01136 22-0790350 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 10, 2023 |
DEFA14A 1 brhc10023253defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission On |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| March 23, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2023 (February 23, 2023) BRISTOL-MYERS SQUIBB COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 001-01136 22-0790350 (State or Other Jurisdiction of |
|
| February 14, 2023 |
EXHIBIT 10aa MARKET SHARE UNITS AGREEMENT UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you the Market Share Units (“MSUs”) specified in the Grant Summary located on the Stock Plan Administrator’s website, which is incorporated into this Market Share Units Agreement (the “Agreement”) and deemed to be a part hereof. |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-01136 BRISTOL-MYERS SQUIBB COMPA |
|
| February 14, 2023 |
EXHIBIT 10w RESTRICTED STOCK UNITS AGREEMENT UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you the Restricted Stock Units (“RSUs”) specified in the Grant Summary located on the Stock Plan Administrator’s website, which is incorporated into this Restricted Stock Units Agreement (the “Agreement”) and deemed to be a part hereof. |
|
| February 14, 2023 |
Section 302 Certification Letter (filed herewith). EXHIBIT 31a CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Giovanni Caforio, certify that: 1. |
|
| February 14, 2023 |
EXHIBIT 10y RESTRICTED STOCK UNITS AGREEMENT UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you the Restricted Stock Units (“RSUs”) specified in the Grant Summary located on the Stock Plan Administrator’s website, which is incorporated into this Restricted Stock Units Agreement (the “Agreement”) and deemed to be a part hereof. |
|
| February 14, 2023 |
EXHIBIT 10x RESTRICTED STOCK UNITS AGREEMENT UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you the Restricted Stock Units (“RSUs”) specified in the Grant Summary located on the Stock Plan Administrator’s website, which is incorporated into this Restricted Stock Units Agreement (the “Agreement”) and deemed to be a part hereof. |
|
| February 14, 2023 |
Section 906 Certification Letter (filed herewith). EXHIBIT 32b Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U. S. C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the Report), as filed with the S |
|
| February 14, 2023 |
EXHIBIT 10i PERFORMANCE SHARE UNITS AGREEMENT Under the Bristol-Myers Squibb Company 2021 Stock Award and Incentive Plan 2023-2025 Performance Share Units Award BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you the Performance Share Units (“Performance Share Units”) specified in the Grant Summary located on the Stock Plan Administrator’s website. |
|
| February 14, 2023 |
EXHIBIT 10z RESTRICTED STOCK UNITS AGREEMENT UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you the Restricted Stock Units (“RSUs”) specified in the Grant Summary located on the Stock Plan Administrator’s website, which is incorporated into this Restricted Stock Units Agreement (the “Agreement”) and deemed to be a part hereof. |
|
| February 14, 2023 |
Section 302 Certification Letter (filed herewith). EXHIBIT 31b CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David V. |
|
| February 14, 2023 |
s securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 ( EXHIBIT 4a DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K (“Annual Report”) of which this exhibit is a part, Bristol-Myers Squibb Company (“Bristol Myers Squibb,” or “we,” “us” and “our”) had the following classes of securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (i) shares of common stock, $0. |
|
| February 14, 2023 |
Section 906 Certification Letter (filed herewith). EXHIBIT 32a Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U. S. C. Section 1350, I, Giovanni Caforio, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Annual Report on Form 10-K for the year ended December 31, 2022 (the Report), as filed with the |
|
| February 14, 2023 |
EXHIBIT 10v RESTRICTED STOCK UNITS AGREEMENT UNDER THE BRISTOL-MYERS SQUIBB COMPANY 2021 STOCK AWARD AND INCENTIVE PLAN BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation (the “Company”), has granted to you the Restricted Stock Units (“RSUs”) specified in the Grant Summary located on the Stock Plan Administrator’s website, which is incorporated into this Restricted Stock Units Agreement (the “Agreement”) and deemed to be a part hereof. |
|
| February 14, 2023 |
Subsidiaries of the Registrant (filed herewith). EXHIBIT 21 Subsidiaries of Bristol-Myers Squibb Company The following are subsidiaries of the Bristol-Myers Squibb Company at December 31, 2022. |
|
| February 9, 2023 |
BMY / Bristol-Myers Squibb Co / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Bristol-Myers Squibb Co. Title of Class of Securities: Common Stock CUSIP Number: 110122108 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fil |
|
| February 2, 2023 |
Exhibit 99.2 BRISTOL-MYERS SQUIBB COMPANY QUARTERLY TREND ANALYSIS OF REVENUES (Unaudited, dollars in millions) Revenues 2021 2022 % Change FX Impact(b) 1st Qtr 2nd Qtr 6 Months 3rd Qtr 9 Months 4th Qtr Year 1st Qtr 2nd Qtr 6 Months 3rd Qtr 9 Months 4th Qtr Year Qtr vs. Qtr YTD vs. YTD Qtr vs. Qtr YTD vs. YTD United States $ 7,010 $ 7,388 $ 14,398 $ 7,296 $ 21,694 $ 7,520 $ 29,214 $ 7,694 $ 8,268 |
|
| February 2, 2023 |
Q4 2022 Results February 2, 2023 Q4 2022 Results Not for Product Promotional Use Forward Looking Statements and Non-GAAP Financial Information 2 This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. |
|
| February 2, 2023 |
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022 Exhibit 99.1 Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022 •Reports Fourth Quarter Revenues of $11.4 Billion; Full-Year Revenues of $46.2 Billion ◦Fourth Quarter Revenues from In-Line Products and New Product Portfolio were $9.0 Billion, an Increase of 7%, or 12% When Adjusted for Foreign Exchange ◦Full-Year Revenues from In-Line Products and New Product Port |
|
| February 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or org |
|
| January 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2023 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or org |
|
| January 9, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 BRISTOL-MYERS SQUIBB COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 1-1136 22-0790350 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| January 9, 2023 |
Exhibit 99.1 January 2023 JP Morgan Presentation Forward Looking Statements and Non-GAAP Financial Information 2 This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe ha |
|
| October 26, 2022 |
Exhibit 99.2 BRISTOL-MYERS SQUIBB COMPANY QUARTERLY TREND ANALYSIS OF REVENUES (Unaudited, dollars in millions) Revenues 2021 2022 % Change FX Impact(b) 1st Qtr 2nd Qtr 6 Months 3rd Qtr 9 Months 4th Qtr Year 1st Qtr 2nd Qtr 6 Months 3rd Qtr 9 Months 4th Qtr Year Qtr vs. Qtr YTD vs. YTD Qtr vs. Qtr YTD vs. YTD United States $ 7,010 $ 7,388 $ 14,398 $ 7,296 $ 21,694 $ 7,520 $ 29,214 $ 7,694 $ 8,268 |
|
| October 26, 2022 |
Section 906 Certification Letter. EXHIBIT 32b Certification by the Chief Financial Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, David V. Elkins, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the "Report"), as filed wit |
|
| October 26, 2022 |
q32022earningspresentati Q3 2022 Results October 26, 2022 Q3 2022 Results Not for Product Promotional Use Forward Looking Statements and Non-GAAP Financial Information 2 This presentation contains statements about Bristol-Myers Squibb Company’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. |
|
| October 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2022 BRISTOL-MYERS SQUIBB COMPANY (Exact name of registrant as specified in its charter) Delaware 001-01136 22-0790350 (State or other jurisdiction of incorporation or org |
|
| October 26, 2022 |
Section 906 Certification Letter. EXHIBIT 32a Certification by the Chief Executive Officer Pursuant to 18 U. S. C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 Pursuant to 18 U.S.C. Section 1350, I, Giovanni Caforio, hereby certify that, to the best of my knowledge, Bristol-Myers Squibb Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the "Report"), as filed wi |
|
| October 26, 2022 |
Section 302 Certification Letter. EXHIBIT 31b CERTIFICATION BY THE CHIEF FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, David V. |
|
| October 26, 2022 |
Section 302 Certification Letter. EXHIBIT 31a CERTIFICATION BY THE CHIEF EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Giovanni Caforio, certify that: 1. |
